Announcements Trials
Browse Landscape

Phase

Phase NA 11Phase 2 10Phase 1 8Phase 3 3Phase EARLY_PHASE1 2Phase 1/2 1

Status

Recruiting 42Active not recruiting 22Not yet recruiting 7Terminated 3Withdrawn 2Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Dermatologic 1

Conditions

Neoplasm Metastasis 1Melanoma 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Cisplatin 111Carboplatin 111pembrolizumab 109Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × Specimen Handling × Clear all
NCT01902173 2025-01-14

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
27 enrolled 16 charts
DermatologicOther hematologic neoplasm

Melanoma, Neoplasm Metastasis, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡